

Special Issue

Advances in Ovarian Cancer Treatment: Past, Present and Future

Message from the Guest Editors

Ovarian cancer is the most lethal gynecological malignancy in relation to cervical and endometrial cancers. It is associated with the worst prognosis and a high mortality rate. In most cases (75%), ovarian cancer is diagnosed at an advanced stage due to its asymptomatic and silent growth of the tumor, delayed onset of symptoms and lack of proper screening. However, important steps have been made in the treatment of advanced ovarian cancer concerning surgery, adjuvant or neoadjuvant chemotherapy drug regimens and maintenance targeted therapy. These resulted in an improved progression-free and overall survival, and a better quality of life of these patients. Nevertheless, even with the new treatment improvements, 80% of the patients will experience recurrence. This Special Issue aims to highlight the current practice and advances in ovarian cancer treatment, including cytoreductive surgery, HIPEC, new chemotherapeutic agents and maintenance targeted therapy.

Guest Editors

Dr. Dimitrios Tsolakidis

1st Department of Obstetrics & Gynecology, Aristotle University of Thessaloniki, "Papageorgiou" General Hospital, Thessaloniki, Greece

Dr. Dimitrios Zouzoulas

1st Department of Obstetrics & Gynecology, Aristotle University of Thessaloniki, "Papageorgiou" General Hospital, Thessaloniki, Greece

Deadline for manuscript submissions

closed (31 December 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/204711

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)